[c09aa8]: / clusters / 9knumclustersv2 / clust_2103.txt

Download this file

111 lines (110 with data), 16.8 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
No major sensory or motor impairment that would preclude valid cognitive testing (e.g., unresolved posterior fossa syndrome, blindness, poorly controlled seizures/photosensitive epilepsy, psychosis) or a major psychological condition that would preclude completion of the intervention (e.g., significant oppositionality, autism spectrum disorder, severe anxiety or depressive symptoms)
Patients with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator)
Patient has any other medical, psychiatric, or social condition, including substance abuse, that in the opinion of the investigator would preclude compliance with the requirements of this study
Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study
Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel).
Cardiac or pulmonary conditions that preclude aggressive cytoreductive surgery
Any electrocardiogram (ECG) abnormality, which in the opinion of the Investigator would preclude safe participation in the study.
Has significant, ongoing, co-morbid conditions which would preclude safe delivery of the study drug.
Medical or psychiatric conditions that preclude informed decision-making or compliance with the protocol treatment or follow-up
Any medical conditions that, in the opinion of the investigator, would preclude use of AGEN, including AGEN hypersensitivity.
Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
Any other health condition that would preclude participation in the study in the judgment of the principal investigator
Psychiatric disorder that would preclude patients from signing an informed consent
Other medical or psychiatric conditions that in the opinion of the investigator would preclude safe participation in the protocol
Have a serious preexisting medical condition that, in the opinion of the investigator would preclude participation in the study (for example a GI disorder causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndrome) or that would result in a life expectancy of less than year
Mental incapacitation or psychiatric illness that would preclude study participation
Any uncontrolled medical or psychiatric disorder that would preclude participation as outlined
Any uncontrolled active medical disorder that would preclude participation as outlined
Any uncontrolled active medical disorder that would preclude participation
Any uncontrolled medical or psychiatric disorder that would preclude participation
History of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion (as per Investigator's judgement) or a psychiatric condition that might impair the subject's well-being or preclude full participation in the trial
Any electrocardiogram (ECG) abnormality that in the opinion of the principal investigator would preclude safe participation in the study
Patients with a history of serious co-morbid illness or uncontrolled illnesses that would preclude protocol therapy.
Patients with psychosocial circumstances or illnesses that preclude protocol participation (to be determined by P.I.)
Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.
Cardiac or pulmonary conditions that preclude aggressive cytoreductive surgery
Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (discretion of the attending physician)
Any uncontrolled active medical disorder that would preclude participation as outlined
Irreversible coagulopathies that preclude fiducial placement
Patients with psychosocial circumstances or illnesses that preclude protocol participation (to be determined by PI)
Co-morbid illnesses that preclude protocol participation (to be determined by PI)
Psychiatric disorder that would preclude patients from signing an informed consent
Other medical or psychiatric conditions that in the opinion of the investigator would preclude safe participation in the protocol
Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
Patients with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator)
Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
Patients with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator)
Patients with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator)
Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study
Serious illness other than cancer that would preclude safe participation in the study.
Medical or psychiatric illness or social situations that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
Any condition that would preclude the ability to deliver appropriate IP therapy
Patients with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator)
History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation.
Has an Underlying medical condition that would preclude study participation.
history or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that would in the investigator's opinion preclude participation in the study or compromise the patient's ability to give informed consent.
Disease or condition that would preclude safe use of TheraSphere, including concurrent dialysis treatment, or unresolved serious infections including patients who are known HIV positive
History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation.
Any uncontrolled active medical disorder that would preclude participation
Any uncontrolled active medical disorder that would preclude participation as outlined
Other uncontrolled, concurrent illness that would preclude study participation; or, psychiatric illness or social challenges that would entail unreasonable risk or preclude informed consent or compliance with study procedures
Any condition, psychiatric, substance abuse, or otherwise, that, in the opinion of the Investigator, would preclude informed consent, consistent follow-up, or compliance with any aspect of the study
Any condition that would preclude informed consent, consistent follow-up and compliance for the study participation
Psychiatric disorder that would preclude patients from signing an informed consent
Patients with psychiatric disability judged by the investigator to be clinically significant so as to preclude informed consent or compliance with drug intake
Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves.
Any uncontrolled active medical disorder that would preclude participation as outlined
Cognitive impairment, history of medical or psychiatric disease, other uncontrolled intercurrent illness, active substance abuse, or social circumstances, which in the view of the principal investigator (PI), would preclude safe treatment or the ability to give informed consent
Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude protocol therapy
Subjects with a clinically significant or unstable medical condition that would preclude safe and complete study participation
No other significant medical or psychiatric problems that would preclude study participation or interfere with capacity to give informed consent.
Uncontrolled or unstable medical or psychiatric co-morbidities which would clearly preclude use of MLN or erlotinib
Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel)
History of medical or psychiatric disease which, in the view of the principal investigator, would preclude safe treatment
Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study therapy drugs.
Have serious preexisting medical conditions that, in the opinion of the investigator, that cannot be adequately controlled with appropriate therapy or would preclude participation in this study
The participant has serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
If a patient has any serious medical problems which may preclude receiving this type of treatment
Any medical condition that would preclude adequate evaluation of the safety and toxicity of the study combination
Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude the patient from being subjected to surgical excision
Central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant to preclude informed consent or interfere with complying with protocol treatments
Psychiatric disorder that would preclude patients from signing an informed consent
Any medical condition that would preclude adequate evaluation of the safety and toxicity of the study combination
The patient has an uncontrolled and active infection that would preclude study conduct and assessment
Patient has any other medical, psychiatric, or social condition, including substance abuse that in the opinion of the investigator would preclude participation in the study.
Any medical co-morbidities that would preclude surgery or radiation therapy
Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.
Illness or any other circumstances (as defined by the investigator), which would preclude safe performance of study procedures or compromise the ability of the patient to consent to study
Clinically significant pulmonary, endocrine, neurologic, hematologic, gastrointestinal (GI), autoimmune, psychiatric or genitourinary disease unrelated to HCC that in the judgment of the investigator should preclude treatment with dalantercept or sorafenib.
Psychiatric disorder or social or geographic situation that would preclude study participation.
If a patient has any serious medical problems which may preclude receiving this type of treatment
Have serious preexisting medical conditions that would preclude participation in the study
History of medical or psychiatric disease, active substance abuse or social circumstances which in the view of the principal investigator, would preclude safe treatment
No known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence
One or more significant medical conditions that in the physicians judgment preclude participation in the walking intervention
Significant psychiatric disturbance verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent (i.e. acute psychiatric symptoms which require individual treatment)
One or more significant medical conditions that in the physicians judgment preclude participation in the walking intervention
Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude epidural placement
Major psychological condition that would preclude completion of the intervention
One or more significant medical conditions or other issues that in the physicians judgment preclude participation in the walking intervention
Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude completion of the assessment measures, interview or informed consent
SUPPORT PROVIDER: Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude completion of the assessment measures, interview or informed consent
Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in the intervention (e.g., acute psychiatric symptoms which requires individual treatment)
One or more significant medical conditions that in the physicians judgment preclude participation in the walking or strength training intervention
One or more significant medical conditions that in the physicians judgment preclude participation in the walking intervention
One or more significant medical conditions that in the treatment teams judgment preclude participation in the walking intervention
Psychiatric disorder that would preclude study participation
Significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the groups (i.e., acute psychiatric symptoms which require individual treatment)
Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude epidural placement
Significant co-morbidities (e.g., diabetes, cardiac disease, or other condition that in the opinion of the primary physician or investigators would limit participation in the intervention groups) that would preclude study participation
Patients must have no significant medical or psychiatric condition that would preclude study completion; tests and exams for this determination should be completed within days prior to registration
Psychiatric disorders or conditions that, in the opinion of the investigator, would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder).
Other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study
Any condition that would preclude the subject from getting the required biopsy as stated in the protocol
Other serious illness (es), which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study
Other serious illness(es) which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study
Significant psychiatric or cognitive disturbance sufficient, in the consenting professional's or investigator's judgment, to preclude providing informed consent or participating in the interventions (i.e., acute psychiatric symptoms which require individual treatment)
Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study.